



Zeal & Innovation in Medicine

Ref No.: ZLL/BM/BSE

Date : 04.08.2020

BSE Limited,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai- 400 001
Company Code- 541400

Dear Sir,

Sub : Outcome of Board Meeting.

Ref : Our Notice dt. 28.07.2020

This is to inform you that the Board of Directors in their meeting held today has inter-alia considered and approved:

- 1) Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June, 2020.
- 2) Reappointment of Walker Chandiook and Co. LLP, as Statutory Auditor for the term of five years commencing from F.Y. 2020-21 subject to the approval of Shareholders of the Company in the Annual General Meeting.

The Board Meeting commenced at 03.00 p.m. and concluded at 05.30 p.m.

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer



Encl : As above.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Nelson Square,
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118,271470
+091.712.2588070

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT,

Nagpur – 440013. Maharashtra, India. Ph.

Walker Chandiook & Co LLP

16th floor, Tower II,
Indiabulls Finance Centre,
SB Marg, Prabhadevi (W)
Mumbai – 400 013
India

T +91 22 6626 2699

F +91 22 6626 2601

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of ZIM Laboratories Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **ZIM Laboratories Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer below for the list of subsidiaries included in the Statement) for the quarter ended 30 June 2020, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

List of wholly owned subsidiaries included in the Statement

ZIM Laboratories FZE
ZIM Health Technologies Limited and
SIA "ZIM Laboratories Limited";

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and as per the presentation requirements of SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.

ZIM Laboratories Limited

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. We draw attention to Note 6 to the accompanying Statement, which indicates delay in receipt of foreign currency receivables by Company aggregating INR 914.88 lakhs as at 30 June 2020, beyond the timelines stipulated vide FED Master Direction No. 16/2015-16, under the Foreign Exchange Management Act, 1999. The management of the Company is in the process of recovering the outstanding dues and is of the view that the fines/penalties, if any, that may be levied pursuant to the delay, are currently unascertainable but are not expected to be material and accordingly, the accompanying Statement does not include any consequential adjustments with respect to such delay/default. Our opinion is not modified in respect of this matter.

For **Walker Chandiook & Co LLP**

Chartered Accountants

Firm Registration No: 001076N/N500013

ADI PERVEZ Digitally signed by
ADI PERVEZ SETHNA
SETHNA Date: 2020.08.04
15:39:11 +05'30'

Adi P. Sethna

Partner

Membership No:108840

UDIN:20108840AAAACZ5060

Place: Mumbai

Date: 04 August 2020




ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2020

(Rs. in lakhs, unless otherwise stated)


Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		(Unaudited)	(Unaudited) (Refer Note 3)	(Unaudited)	(Audited)
1	Income				
	a) Revenue from operations	7,047.59	6,919.57	6,740.74	27,773.92
	b) Other income	62.44	243.22	105.15	452.08
	Total income	7,110.03	7,162.79	6,845.89	28,226.00
2	Expenses				
	a) Cost of materials consumed	3,805.65	2,542.01	3,434.39	13,366.79
	b) Purchases of stock-in-trade	175.42	719.35	659.15	1,587.17
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(396.89)	233.31	(368.57)	(639.97)
	d) Employee benefits	818.90	954.13	889.85	3,534.58
	e) Finance costs	294.31	301.07	324.29	1,265.45
	f) Depreciation and amortisation	385.48	385.85	335.59	1,441.16
	g) Other expenses	1,588.11	1,779.71	1,814.96	7,663.96
	Total expenses	6,670.98	6,915.43	7,089.66	28,219.14
3	Profit/ (Loss) before tax (1-2)	439.05	247.36	(243.77)	6.86
4	Tax expense/ (credit)				
	Current Tax	63.34	(36.61)	-	(12.33)
	Deferred Tax (Refer Note 7)	47.63	54.27	(252.42)	(310.47)
	Total tax expense / (credit)	110.97	17.66	(252.42)	(322.80)
5	Profit after tax (3-4)	328.08	229.70	8.65	329.66
6	Other comprehensive income - profit/(loss)				
	a) Items that will not be reclassified to profit or loss	(9.51)	10.44	(16.16)	(38.04)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	2.77	(3.05)	4.71	11.08
	c) Items that will be reclassified to profit or loss	(3.05)	51.96	(5.38)	61.08
	d) Tax (expense)/credit on the items that will be reclassified to profit or loss	-	-	-	-
	Other comprehensive income (net of tax) - profit/(loss)	(9.79)	59.35	(16.83)	34.12
7	Total comprehensive income (5+6)	318.29	289.05	(8.18)	363.78
8	Paid-up equity share capital (face value of Rs. 10/- each)	1,624.19	1,618.07	1,618.07	1,618.07
9	Other equity (reveluation reserve : Rs. Nil)				13,764.03
10	Earnings per share (face value of Rs. 10/- each) (not annualised) (Rs.)				
	Basic	2.02	1.41	0.05	2.03
	Diluted	2.02	1.41	0.05	2.03



Notes :

- 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 04 August 2020. There are no qualifications in the limited review report issued for the quarter ended 30 June 2020.
- 2) These financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) notified under the Companies (Ind AS) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended.
- 3) The figures for the quarter ended 31 March 2020 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2020 and the unaudited year-to-date figures upto 31 December 2019, on which auditors had performed a limited review.
- 4) The Group is principally engaged in a single business segment which is "pharmaceuticals".
- 5) During the quarter ended 30 June 2019, the Company has acquired entire shareholding in 'Zim Health Technologies Limited' and during the quarter ended 30 September 2019, the Company has incorporated wholly owned subsidiary 'SIA ZIM Laboratories Limited' in Latvia. Accordingly, the current period consolidated financial results include financial results of the Company, Zim Laboratories FZE, Zim Health Technologies Limited and SIA ZIM Laboratories Limited.
- 6) Trade receivables, of the parent Company, outstanding as at 30 June 2020, include balances aggregating Rs.914.88 lakhs from customers situated outside India. These balances are outstanding for a period, beyond the timelines stipulated vide FED Master Direction No. 16/2015-16, under the Foreign Exchange Management Act, 1999. The Company is in the process of recovering the outstanding dues. The amount of fine/penalty, if any, that may be levied, is currently unascertainable but is not expected to be material and accordingly, the accompanying Consolidated financial results do not include any consequential adjustments that may arise due to such delay/default.
- 7) Deferred tax credit for the quarter ended 30 June 2019 and year ended 31 March 2020, includes credit due to impact of applicable tax rates from 34.94% to 29.12% on net deferred tax liabilities (excluding MAT Credit Entitlement Assets) as at 1 April 2019.

Place: Nagpur
Date: 04 August 2020


Anwar S. Daud
Managing Director



Walker Chandiook & Co LLP

16th floor, Tower II,
Indiabulls Finance Centre,
SB Marg, Prabhadevi (W)
Mumbai – 400 013
India

T +91 22 6626 2699

F +91 22 6626 2601

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of ZIM Laboratories Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **ZIM Laboratories Limited** ('the Company') for the quarter ended 30 June 2020, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and as per the presentation requirements of SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and as per the presentation requirements of the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

ZIM Laboratories Limited

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

5. We draw attention to Note 5 to the accompanying Statement, which indicates delay in receipt of foreign currency receivables, aggregating INR 914.88 lakhs as at 30 June 2020, beyond the timelines stipulated vide FED Master Direction No. 16/2015-16, under the Foreign Exchange Management Act, 1999. The management of the Company is in the process of recovering the outstanding dues and is of the view that the fines/penalties, if any, that may be levied pursuant to the delay, are currently unascertainable but are not expected to be material and accordingly, the accompanying Statement does not include any consequential adjustments with respect to such delay/default. Our opinion is not modified in respect of this matter.

For **Walker Chandiok & Co LLP**

Chartered Accountants

Firm Registration No:001076N/N500013

ADI PERVEZ Digitally signed by
ADI PERVEZ SETHNA
SETHNA Date: 2020.08.04
15:38:22 +05'30'

Adi P. Sethna

Partner

Membership No:108840

UDIN:20108840AAAACY5580

Place: Mumbai

Date: 04 August 2020



ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2020

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Year ended
		30.06.2020	31.03.2020	30.06.2019	31.03.2020
		(Unaudited)	(Unaudited) (Refer Note 3)	(Unaudited)	(Audited)
1	Income				
	a) Revenue from operations	6,977.20	6,793.20	6,685.59	27,431.97
	b) Other income	64.41	245.35	112.01	465.65
	Total income	7,041.61	7,038.55	6,797.60	27,897.62
2	Expenses				
	a) Cost of materials consumed	3,805.65	2,542.01	3,434.39	13,366.79
	b) Purchases of stock-in-trade	175.42	719.35	659.15	1,587.17
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(396.89)	233.31	(368.57)	(639.97)
	d) Employee benefits	798.11	928.51	879.74	3,458.42
	e) Finance costs	294.31	301.07	324.29	1,265.45
	f) Depreciation and amortisation	355.46	355.77	308.22	1,327.15
	g) Other expenses	1,621.95	1,789.67	1,810.13	7,681.35
	Total expenses	6,654.01	6,869.69	7,047.35	28,046.36
3	Profit/ (Loss) before tax (1-2)	387.60	168.86	(249.75)	(148.74)
4	Tax expense/ (credit)				
	Current Tax	63.34	(36.61)	-	(12.33)
	Deferred Tax (Refer Note 6)	47.63	54.27	(252.41)	(310.47)
	Total tax expense / (credit)	110.97	17.66	(252.41)	(322.80)
5	Profit after tax (3-4)	276.63	151.20	2.66	174.06
6	Other comprehensive income - profit/(loss)				
	a) Items that will not be reclassified to profit or loss	(9.51)	10.44	(16.16)	(38.04)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	2.77	(3.05)	4.71	11.08
	Other comprehensive income (net of tax) - profit/(loss)	(6.74)	7.39	(11.45)	(26.96)
7	Total comprehensive income (5+6)	269.89	158.59	(8.79)	147.10
8	Paid-up equity share capital (face value of Rs. 10/- each)	1,624.19	1,618.07	1,618.07	1,618.07
9	Other equity (reveluation reserve : Rs. Nil)				13,557.45
10	Earnings per share (face value of Rs. 10/- each) (not annualised) (Rs.)				
	Basic	1.70	0.93	0.02	1.07
	Diluted	1.70	0.93	0.02	1.07



Notes :

- 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 04 August 2020. There are no qualifications in the limited review report issued for the quarter ended 30 June 2020.
- 2) These financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) notified under the Companies (Ind AS) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 as amended.
- 3) The figures for the quarter ended 31 March 2020 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2020 and the unaudited year to date figures upto 31 December 2019, on which auditors had performed a limited review.
- 4) The Company is principally engaged in a single business segment which is "pharmaceuticals".
- 5) Trade receivables outstanding as at 30 June 2020, include balances aggregating Rs.914.88 lakhs from customers situated outside India. These balances are outstanding for a period, beyond the timelines stipulated vide FED Master Direction No. 16/2015-16, under the Foreign Exchange Management Act, 1999. The Company is in the process of recovering the outstanding dues. The amount of fine/penalty, if any, that may be levied, is currently unascertainable but is not expected to be material and accordingly, the accompanying standalone financial results do not include any consequential adjustments that may arise due to such delay/default.
- 6) Deferred tax credit for the quarter ended 30 June 2019 and year ended 31 March 2020, includes credit due to impact of applicable tax rates from 34.94% to 29.12% on net deferred tax liabilities (excluding MAT Credit Entitlement Assets) as at 1 April 2019.

Place: Nagpur
Date: 04 August 2020


Anwar S. Daud
Managing Director

